- HER2+ Breast Cancer
- HER2 Low Breast Cancer
- HER2+ Gastric Cancer
- Other HER2+ Cancers
Human epidermal growth factor receptor 2, or HER2, is a gene that encodes a protein that promotes cell growth and differentiation. HER2 protein overexpression and gene amplification have been documented across multiple cancers. Previous targeting of HER2 has had a major impact on the subset of patients with HER2-expressing breast and gastric cancer, but there remains a huge amount of work to be done highlighted by a significant individual and global patient need. HER2-positive has been identified in a wide range of malignancies including breast, gastric, bladder, lung, esophageal, colorectal, ovarian, salivary gland, pancreatic, cervical cancers, and others.
Our lead product candidate, BDC-1001, seeks to improve therapeutic outcomes for patients with HER2-expressing tumors by targeting: 1) HER2-positive breast and gastric cancer refractory to existing anti-HER2 therapies, 2) tumors with lower expression of HER2 that are not eligible for approved therapies, and 3) other HER2-positive tumors not eligible for approved therapies. In addition, our innovative BDC-1001 approach seeks to address this critically important unmet medical need not only in patients with advanced tumors, but also in adjuvant settings.
- Non-Small Cell Lung Cancer
- Colorectal Cancer
- Pancreatic Cancer
- Breast Cancer
Our carcinoembryonic antigen (CEA) program focused on the well-known tumor antigen that is overexpressed in various solid tumors with significant unmet medical need including, but not limited to, colorectal cancer, non-small cell lung cancer, pancreatic cancer, and breast cancer. CEA allows us to target these cancers, some of which are immunologically “cold”. CEA is upregulated on the cell surface of these cancers and displays minimal receptor-mediated internalization into the cancer cell.
Our PD-L1 Boltbody ISAC focuses on another area with significant unmet medical need, the treatment of patients with tumors that are nonresponsive or become refractory to immune checkpoint blockade. This encompasses more than 15 different tumor types impacting the lives of millions of patients yearly. Our PD-L1 program is a trifunctional therapeutic with the following mechanism: 1) antibody-dependent cellular phagocytosis of the tumor, 2) myeloid activation and adaptive T cell response, and 3) PD-L1/PD-1 checkpoint inhibition.
Our Myeloid Modulator Platform reawakens myeloid cells to attack tumor cells. We identified monoclonal antibodies that are capable of binding to and agonizing a novel cell surface protein (referred to as TAM1) on tumor-supportive macrophages. The activation of these macrophages results in the production of pro-inflammatory cytokines, consistent with the characteristics of tumor-destructive macrophages. TAM1 may have the potential to reprogram tumor-supportive macrophages into tumor-destructive macrophages to elicit a productive anti-tumor immune response. Additionally, KRAS and TP53 mutations may upregulate TAM1 on tumor-associated myeloid cells and could provide an avenue to develop precision medicine with an immune modulator.
BDC-1001 is a Boltbody™ ISAC that is currently in clinical development for the treatment of patients with HER2-expressing solid tumors, including subsets with HER2-low tumors. We have designed BDC-1001 as an ISAC comprised of a HER2-targeting biosimilar trastuzumab conjugated to one of our proprietary TLR7/8 agonists to maximize the potential anti-tumor response.
BDC-1001 stimulates anti-tumor activity with a three-pronged approach: direct tumor cell killing by trastuzumab-mediated mechanisms, localized phagocytosis and elimination of HER2-expressing tumor cells by activated myeloid APCs, and durable immunity manifested by T cells reactive to tumor-associated antigens or neoantigens. These mechanisms are supported by our in vivo data demonstrating tumor elimination and immunological memory when treated with our BDC-1001 surrogates.
BDC-2034 is a Boltbody™ ISAC that is in development for the treatment of various solid tumors. In designing BDC-2034, we selected a monoclonal antibody with selective binding to CEACAM5, also known as carcinoembryonic antigen (CEA), that displays high levels of antibody-dependent cellular phagocytosis of CEA-expressing cancer cells. We then created an ISAC by conjugating one of our proprietary TLR7/8 agonists to this mAb. In our preclinical studies, we have observed robust myeloid cell activation in vitro and promising anti-tumor activity in vivo.
CEA is a well-known tumor antigen that is overexpressed in various solid tumors with significant unmet medical need including, but not limited to, colorectal cancer, non-small cell lung cancer, pancreatic cancer and breast cancer. CEA is upregulated on the cell surface of these cancers and displays minimal receptor-mediated internalization into the cancer cell. Therefore, CEA allows us to target these cancers, some of which are immunologically “cold,” with an ISAC and offers the potential to turn these “cold” tumors into “hot” tumors with a robust immunological response.